What is the Origin of Lipopolysaccharide Reduction?

This concept is fundamentally linked to the discovery of "leaky gut" or increased intestinal permeability and its systemic consequences. Research in immunology and gastroenterology identified LPS as a key pathological mediator connecting gut barrier dysfunction to chronic inflammatory states and metabolic disorders. The term reflects a targeted clinical response to this identified source of systemic inflammation.

What is the Mechanism of Lipopolysaccharide Reduction?

Reduction is achieved primarily by strengthening the intestinal epithelial barrier, often through targeted nutritional and supplemental interventions that support the tight junction proteins. Additionally, modulating the gut microbiome to reduce the population of LPS-producing Gram-negative bacteria and increasing the production of barrier-supportive short-chain fatty acids are critical steps. By limiting LPS translocation, the systemic inflammatory cascade, mediated by toll-like receptor 4 (TLR4) signaling, is effectively dampened.

Lipopolysaccharide Reduction

Meaning

Lipopolysaccharide Reduction is the therapeutic strategy aimed at decreasing the circulating levels of lipopolysaccharides (LPS), which are potent pro-inflammatory molecules derived from the outer membrane of Gram-negative bacteria in the gut. Elevated systemic LPS, often referred to as endotoxemia, is a significant driver of chronic low-grade inflammation, insulin resistance, and hormonal dysregulation. The clinical goal is to minimize the translocation of this toxin from the intestinal lumen into the bloodstream.